{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:58Z","timestamp":1786988038817,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-158"],"award-info":[{"award-number":["BCRF-158"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["180712"],"award-info":[{"award-number":["180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031283","name":"Sanofi France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116152","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:48:14Z","timestamp":1764607694000},"page":"116152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score\u00ae in node-positive breast cancer: Independent validation in the PACS-01 trial"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5492","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-5536","authenticated-orcid":false,"given":"Amelie","family":"Lusque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0659","authenticated-orcid":false,"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Lacroix-Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-2168","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Fraser Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116152_bib1","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2011-0442","article-title":"Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial","volume":"17","author":"Coudert","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.116152_bib3","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116152_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116152_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116152_bib7","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116152_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12885-018-4331-8","article-title":"The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)","volume":"18","author":"Penault-Llorca","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.116152_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/clinchem\/hvaa105","article-title":"Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue","volume":"66","author":"Lau","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2025.116152_bib10","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/hvab068","article-title":"Intra- and interlaboratory reproducibility of the sensitivity to endocrine therapy assay for stage II\/III breast cancer","volume":"67","author":"Bossuyt","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2025.116152_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.annonc.2021.02.011","article-title":"Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+\/HER2-) breast cancer before chemo-endocrine therapy","volume":"32","author":"Du","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-019-0111-0","article-title":"SET-ER\/PR - a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","volume":"5","author":"Sinn","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2025.116152_bib13","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-22-0068","article-title":"Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (alliance Z1031)","volume":"28","author":"Suman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116152_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO-24-01875","article-title":"Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer","volume":"43","author":"Metzger Filho","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib15","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1200\/JCO.22.01499","article-title":"Evaluation of the sensitivity to endocrine therapy index and 21-gene breast recurrence score in the SWOG S8814 trial","volume":"41","author":"Speers","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib16","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.02863","article-title":"Prognostic tests in early-stage hormone receptor-positive breast cancer: an opportunity to refine personalized cancer care","volume":"41","author":"LeVasseur","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib17","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.20.00853","article-title":"Molecular drivers of oncotype DX, prosigna, endopredict, and the breast cancer index: a transATAC study","volume":"39","author":"Buus","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116152_bib20","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492501038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492501038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:13:42Z","timestamp":1778624022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492501038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"alternative-id":["S095980492501038X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116152","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score\u00ae in node-positive breast cancer: Independent validation in the PACS-01 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116152"}}